EVC/EVC2的致癌性激活界定了一个可治疗性靶向的急性髓系白血病亚群
研究鉴定EVC和EVC2在部分急性髓系白血病(AML)中异常高表达,尤其伴ASXL1突变或t(8;21)易位者,高表达与预后差相关。功能实验显示EVC/EVC2对AML细胞致白血病特性必需,而对正常造血干/祖细胞非必需;其缺失可抑制增殖、促进分化并阻断体内AML进展。机制上EVC/EVC2通过激活MYC通路发挥致癌作用,不依赖经典Hedgehog信号。
要点
- EVC/EVC2在伴ASXL1突变或t(8;21)的AML亚群中高表达,且高表达与预后差相关。
- EVC/EVC2为AML细胞致白血病特性所必需,对正常造血干/祖细胞非必需。
- EVC/EVC2通过MYC通路激活发挥致癌作用,不依赖经典Hedgehog信号。
核心结论
- EVC/EVC2过表达构成AML中的致癌事件,并揭示新的治疗脆弱性。
研究设计与样本
- 研究识别EVC和EVC2在部分AML中异常过表达,并进行功能与机制研究。
主要发现
- EVC/EVC2在伴ASXL1突变或t(8;21)易位的AML中过表达,高表达与患者预后差相关。
- EVC/EVC2缺失损害白血病细胞增殖、促进分化并有效阻断体内AML进展。
- EVC/EVC2的致白血病作用通过MYC通路激活介导,独立于其经典Hedgehog信号作用。
关键数值与推荐
- 伴t(8;21)的AML细胞中EVC/EVC2启动子区获得AML1-ETO占据。
- 伴ASXL1突变的AML细胞中EVC/EVC2启动子区染色质相互作用增强。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by high incidence, poor prognosis, and marked genetic and clinical heterogeneity. This heterogeneity poses a significant challenge to effective treatment and underscores the urgent need for tailored therapeutic strategies. Here, we identified the EvC ciliary complex subunits EVC and EVC2 as aberrantly overexpressed in a subset of AMLs, particularly those harboring ASXL1 mutations or the t(8;21) translocation, with elevated expression correlating with poor patient prognosis. Functional studies demonstrated that EVC/EVC2 are essential for maintaining the leukemogenic properties of AML cells, while being dispensable for the function of normal hematopoietic stem/progenitor cells. Loss of EVC/EVC2 impairs leukemia cell proliferation, promotes differentiation, and effectively blocks AML progression in vivo. Mechanistically, we revealed that elevated EVC/EVC2 expression is associated with gained AML1-ETO occupancy or enhanced chromatin interactions at EVC/EVC2 promoter regions in AML cells carrying t(8;21) or ASXL1 mutations, respectively. Notably, we demonstrate that the leukemogenic role of EVC/EVC2 is mediated through MYC pathway activation, independent of their canonical role in Hedgehog signaling. Collectively, our findings demonstrate an oncogenic event of overexpressed EVC/EVC2, identifying novel therapeutic vulnerabilities in AML.
引用
- Sui P, Li Y, Hong J, et al. Oncogenic activation of EVC/EVC2 defines a therapeutically targetable subset of acute myeloid leukemia. Leukemia. 2025. PMID: 41249566. doi:10.1038/s41375-025-02803-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。